J Oral Med Oral Surg
Volume 28, Number 4, 2022
|Number of page(s)||5|
|Published online||21 December 2022|
Diagnosis, treatment and recurrence of a mandibular Langerhans cell histiocytosis: a three-year follow-up case report
Nantes Dental School, Nantes University Hospital, Nantes, France
2 Private Practice, Angers, France
3 Department of Oral and Maxillofacial Surgery, Saint-Nazaire, France
4 Department of Oral and Maxillofacial Surgery, Nantes University Hospital, Nantes, France
5 Department of Internal Medicine, Nantes University, Nantes University Hospital, Nantes, France
6 Department of Oral Surgery, Nantes University, Nantes University Hospital, INSERM UMR-S 1229, RMeS, Nantes, France
* Correspondence: email@example.com
Accepted: 11 September 2022
Introduction: Langerhans cell histiocytosis (LCH) is an abnormal clonal proliferation of Langerhans cells secondary to immune process, mutation of oncogene or genetic predispositions. It preferentially affects bone, lung and skin. The incidence is 2–6 cases per million per year. Prognosis is variable and depends on number and location of lesions, and impact of the initial treatment. Oral lesions may be the first sign of LCH as illustrated by the present case. Observation: A 24-year-old male consulted first for severe gingival inflammation, teeth mobilities and alveolar bone loss with a suspicion of LCH. A pulmonary involvement was secondarily revealed by tomodensitometry. Histological examination, from gingival biopsy, confirmed the diagnostic of LCH, showing cells positive for the anti-CD1A antibody. The patient was managed by oral surgery and chemotherapy approaches. Alveolar bone loss significantly reduced. But 2 years and a half after the diagnosis, a recurrence was noted and managed by surgical approach. After a three-year follow-up, no recurrence was noted. Conclusion: Oral lesions can be inaugural manifestations of LCH. The dentist has an essential role in the early detection of these lesions.
Key words: histiocytosis / langerhans cells / mandible
© The authors, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.